市場調查報告書
商品編碼
1424834
基因組學市場:按技術、應用、最終用戶、服務劃分-全球預測(至2031年)Genomics Market by Technology, Application, End User, Offering - Global Forecast to 2031 |
到 2031 年,全球基因組學市場預計將達到 705.2 億美元,2024 年至 2031 年複合年增長率為 11.1%。
經過廣泛的二次和初步研究以及對市場情景的詳細分析,本報告對關鍵行業驅動因素、限制因素、挑戰和機會進行了分析。 基因組學市場的成長是由遺傳患者病率上升、基因組學數據越來越多地融入臨床工作流程、增加基因組學計畫的資金和投資、擴大基因組學在醫療保健和製藥中的應用所推動的。驅動因素包括研發支出的增加、降低定序成本並增加醫療保健支出。 然而,基因組學缺乏標準化方法以及對基因組學資料安全和隱私的擔憂正在限制該市場的成長。
此外,個人化藥物和基因治療的日益普及預計將創造市場成長機會。 然而,缺乏熟練的生物資訊學和基因組學人才、基因組學技術的商業化和擴展給市場利益相關者帶來了重大挑戰。
本報告是基於對領先市場參與者在四年期間(2020-2024 年)的產品組合、區域影響力和關鍵策略發展的廣泛評估,提供了競爭格局。 全球基因組學市場的主要參與者包括安捷倫科技公司(美國)、Bio-Rad Laboratories, Inc.(美國)、丹納赫公司(美國)、賽默飛世爾科技公司(美國)、Illumina, Inc. (美國) )、QIAGEN N.V.(荷蘭)、Pacific Biosciences of California, Inc.(美國)、Oxford Nanopore Technologies Plc.(英國)、Eppendorf SE(德國)、Myriad Genetics, Inc.(美國)、Revvity, Inc. (原PerkinElmer) , Inc. 美國)和華大基因有限公司(中國)。
在本報告研究的所有產品中,消耗品領域預計在預測期內複合年增長率最高。 此細分市場複合年增長率最高的原因是遺傳疾病盛行率不斷上升、基因檢測的採用率增加以及消耗品而非設備的定期購買。 遺傳疾病的日益普及推動了對基因檢測的需求,從而推動了耗材的採用。 例如,根據美國MJH生命科學公司2022年發布的報告,全球每年約有30萬個嬰兒出生時患有鐮狀細胞疾病,全球近5%的人口受到鐮狀細胞疾病的影響。
在本報告調查的所有技術中,聚合□鍊式反應 (PCR) 領域預計將在 2024 年佔據基因組學市場的最大份額。 PCR 在臨床診斷中的使用增加、PCR 技術的進步、基因組學研究的合作研究以及 PCR 在這些研究調查中的使用是促成該細分市場最大份額的一些因素。 產品的推出進一步提高了該細分市場的重要市場份額。 例如,2023 年 3 月,Bio-Rad Laboratories 推出了 PTC Tempo 96 和 PTC Tempo Deepwell 熱循環儀,以優化定序、克隆和基因分型等 PCR 應用。
在本報告研究的所有應用中,診斷領域預計將在 2024 年佔據基因組學市場的最大份額。 基因組學在腫瘤學、新生兒篩檢和肝炎檢測中的應用佔據了這一領域的最大份額。 新生兒篩檢是對新生兒進行的測試,旨在識別已知的遺傳性疾病。 政府機構支持新生兒篩檢,透過早期發現、診斷和介入來降低新生兒遺傳疾病的發生率。 例如,2022年12月,英國政府投資超過1.106億美元(1.05億英鎊)來加速新生兒罕見疾病的診斷速度。 此類舉措在推動該細分市場的最大份額方面發揮關鍵作用。
在本報告研究的所有最終用戶中,製藥和生技公司領域預計在預測期內複合年增長率最高。 該領域複合年增長率最高的原因是製藥和生物技術公司研發的增加、研究方法中基因組學利用率的提高以及生物技術公司數量的增加。 此外,慢性病的盛行率日益增加,加速了藥物開發進程的需要,並進一步推動了製藥公司採用基因組學。
對全球基因組學市場區域狀況的詳細分析提供了五個主要區域(北美、歐洲、亞太地區、拉丁美洲、中東和非洲)的詳細定性和定量見解,並提供了關鍵國家覆蓋範圍。 到 2024 年,北美預計將佔據基因組學市場的最大份額。 北美擁有許多專門從事基因組學研究的著名研究機構、大學和組織。 由於藥物研發支出的增加和大公司的存在,該地區正在為癌症基因組學做出重大貢獻。 例如,在加拿大,製藥公司正在增加藥物發現的研發支出,從而推動了對基因組學的需求。 例如,2020 年加拿大製藥業的研發總支出預計在 18 億美元至 24 億美元之間,而 2019 年為 16 億美元至 22 億美元。 因此,研究機構的存在、遺傳疾病檢測的增加以及藥品研發支出的增加支撐著最大的區域份額。
(註:包含前5名公司的SWOT分析)
Genomics Market by Technology (Sequencing, Microarray, PCR, Nucleic Acid Extraction) Application (Drug Discovery, Diagnostic, Research) End User (Pharmaceutical, Hospital, Academic) Offering (Instrument, Consumable, Software)-Global Forecast to 2031
The global genomics market is projected to reach $70.52 billion by 2031, at a CAGR of 11.1% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the genomics market is driven by the rising prevalence of genetic diseases, the increasing incorporation of genomic data in clinical workflows, increasing funding and investments in genomics projects, the growing applications of genomics in the healthcare sector, rising pharmaceutical R&D expenditures, decreasing cost of sequencing, and increasing healthcare spending. However, the lack of standardized approaches in genomics and concerns over the security & privacy of genomic data restrain the growth of this market.
Moreover, the rising adoption of personalized medicines and gene therapies is expected to generate market growth opportunities. However, the shortage of skilled bioinformatics and genomics personnel and the commercialization and scaling of genomic technologies are major challenges for market stakeholders.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2024). The key players operating in the global genomics market are Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Eppendorf SE (Germany), Myriad Genetics, Inc. (U.S.), Revvity, Inc. (Formerly PerkinElmer, Inc.) (U.S.), and BGI Genomics Co. Ltd (China).
Among all the offerings studied in this report, the consumables segment is projected to register the highest CAGR during the forecast period. The highest CAGR of this segment is attributed to the increasing prevalence of genetic diseases, growing adoption of genetic testing, and recurring purchase of consumables over instruments. An increase in the prevalence of genetic disease cases has triggered the demand for genetic tests, which is driving the adoption of consumables. For instance, according to a report published by MJH Life Sciences (U.S.) in 2022, approximately 300,000 babies are born with sickle cell disease per year globally, and nearly 5% of the world's population is affected by the disease.
Among all the technologies studied in this report, in 2024, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the genomics market. The increasing use of PCR in clinical diagnostics, technological advancements in PCR, collaborations for genomic research, and the use of PCR in these research studies are some of the factors contributing to the segment's largest share. Product launches further boost this segment's large market share. For instance, in March 2023, Bio-Rad Laboratories launched PTC Tempo 96 and PTC Tempo Deepwell Thermal Cyclers to optimize PCR applications such as sequencing, cloning, and genotyping.
Among all the applications studied in this report, in 2024, the diagnostics segment is expected to account for the largest share of the genomics market. The use of genomics in oncology, newborn screening, and hepatitis testing is contributing to the largest share of the segment. Genomics is used in newborn screening, which are laboratory tests performed on newborn babies to identify known genetic diseases. Government agencies support newborn screening to reduce the incidence of genetic disorders among newborns through early detection, diagnosis, and intervention. For instance, in December 2022, the government of the U.K. invested more than USD 110.6 million (GBP 105 million) to speed up the rare disease diagnosis in newborns. Such initiatives play a vital role in driving the segment's largest share.
Among all the end users studied in this report, the pharmaceutical & biotechnology companies' segment is expected to record the highest CAGR during the forecast period. The highest CAGR of the segment is attributed to the increasing research & development by pharmaceutical & biotechnology companies, the rising utilization of genomics for research processes, and an increasing number of biotechnology companies. Moreover, the rising incidence of chronic diseases has accelerated the need to expedite drug development processes, further propelling the adoption of genomics among pharmaceutical companies.
An in-depth analysis of the geographical scenario of the global genomics market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of the genomics market. North America is home to numerous renowned research institutions, universities, and organizations dedicated to genomics research; the region has made significant contributions to cancer genomics, with rising pharmaceutical R&D expenditure and the presence of key players. For instance, R&D spending by pharmaceutical companies in Canada for drug discovery has increased, driving the demand for genomics. For instance, in 2020, total R&D expenditure in Canada's pharmaceutical sector was estimated at between USD 1.8 billion and USD 2.4 billion, compared to USD 1.6 billion and USD 2.2 billion in 2019. Thus, the presence of research institutes, rising testing for genetic disorders, and increasing pharmaceutical R&D expenditure is supporting the largest regional share.
Genomics Market Assessment-by Offering
Genomics Market Assessment-by Technology
Note: Other sequencing technologies include pyrosequencing, degradome sequencing, sanger sequencing, chromatin immunoprecipitation (ChIP) sequencing, and methylation sequencing.
Note: Other technologies include cell counting, transfection, and gene editing.
Genomics Market Assessment-by Application
Note: Other life sciences research applications include cardiovascular research, osteoporosis, immunology, neurobiology, cellular and molecular biology, and diabetes
Note: Other applications include agriculture, forensics, and environmental.
Genomics Market Assessment-by End User
Note: Other end users include food & beverage companies, agriculture companies, and forensics.
Genomics Market Assessment-by Geography
(Note: SWOT Analysis of Top 5 Companies is Provided)